Related coverage linked through entity extraction aliases.
Aug 15, 2026
Valneva withdrew its U.S. BLA and IND for chikungunya vaccine Ixchiq after an FDA clinical hold tied to a serious adverse event. The company reported a wider FY2025 net loss of €115.2 million, while its Lyme vaccine VLA15 showed over 70% efficacy in Phase III.
Apr 20, 2026
Pfizer and Valneva said their investigational Lyme disease vaccine candidate showed more than 70% efficacy in the phase 3 VALOR trial. Pfizer plans regulatory submissions after the study, which reported no safety concerns at the time of analysis.
Apr 04, 2026
Pfizer and Valneva said their investigational Lyme disease vaccine showed more than 70% efficacy in the Phase 3 VALOR trial with a favorable safety profile. The companies plan regulatory submissions despite the trial missing its primary statistical criterion due to fewer Lyme cases than expected.
